Using a higher cutoff for the percentage of HER2+cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis

被引:18
作者
Hameed, Omar [1 ]
Adams, Amy L. [1 ]
Baker, Allyson C. [1 ]
Balmer, Nicole E. [1 ]
Bell, Walter C. [1 ]
Burford, Holly N. [1 ]
Chhieng, David C. [1 ]
Jhala, Nirag C. [1 ]
Klein, Michael J. [1 ]
Winokur, Thomas [1 ]
机构
[1] Univ Alabama Birmingham, Div Anat Pathol, Sch Med, Dept Pathol, Birmingham, AL 35294 USA
关键词
breast carcinoma; HER2; immunohistochemistry; interobserver variability; cutoff value;
D O I
10.1309/KETM3HANLUQHW7YV
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The effect of using a 30% cutoff for the proportion of HER2+ cells on the interobserver variability in the interpretation of GER2 immunohistochemical results was evaluated. Immunostained sections from 96 cases of breast carcinoma were reviewed by 10 pathologists and scored as positive (3+) when uniform strong membranous staining was identifies in at least 10% of tumor cells; the actual percentage of cells with such staining was also estimated. The agreement rates and the kappa values using a 30% cutoff were compared with those using a 10% cutoff were compared with those using a 10% cutoff. These proved to be higher in 62% and 66% of measurements, respectively, with average interobserver rates and kappa values of 72% and 0.54 using the 30% cutoff and 70% and 0.49 using the 10% cutoff (P = .001 for all comparisons). Using a 30% cutoff for the percentage of HER2+ cells by immunohistochemical analysis modestly decreased interobserver variability in the interpretation of HER2 immunohistochemical results.
引用
收藏
页码:425 / 427
页数:3
相关论文
共 10 条
[1]  
Carlson Robert W, 2006, J Natl Compr Canc Netw, V4 Suppl 3, pS1
[2]   Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma? [J].
Hameed, Omar ;
Chhieng, David C. ;
Adams, Amy L. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007, 128 (05) :825-829
[3]  
Hsu CY, 2002, AM J CLIN PATHOL, V118, P693
[4]   Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer [J].
Joensuu, H ;
Kellokumpu-Lehtinen, P ;
Bono, P ;
Alanko, T ;
Kataja, V ;
Asola, R ;
Utriainen, T ;
Kokko, R ;
Hemminki, A ;
Tarkkanen, M ;
Turpeenniemi-Hujanen, T ;
Jyrkkiö, S ;
Flander, M ;
Helle, L ;
Ingalsuo, S ;
Johansson, K ;
Jääskeläinen, A ;
Pajunen, M ;
Rauhala, M ;
Kaleva-Kerola, J ;
Salminen, T ;
Leinonen, M ;
Elomaa, I ;
Isola, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :809-820
[5]   Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables [J].
Ménard, S ;
Valagussa, P ;
Pilotti, S ;
Gianni, L ;
Biganzoli, E ;
Boracchi, P ;
Tomasic, G ;
Casalini, P ;
Marubini, E ;
Colnaghi, MI ;
Cascinelli, N ;
Bonadonna, G .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :329-335
[6]   HER2 and responsiveness of breast cancer to adjuvant chemotherapy [J].
Pritchard, KI ;
Shepherd, LE ;
O'Malley, FP ;
Andrulis, IL ;
Tu, DS ;
Bramwell, VH ;
Levine, MN .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (20) :2103-2111
[7]   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].
Slamon, DJ ;
Leyland-Jones, B ;
Shak, S ;
Fuchs, H ;
Paton, V ;
Bajamonde, A ;
Fleming, T ;
Eiermann, W ;
Wolter, J ;
Pegram, M ;
Baselga, J ;
Norton, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792
[8]  
Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO
[9]  
2
[10]  
Zarbo RJ, 2003, ARCH PATHOL LAB MED, V127, P549